Loading…
CRL
Charles River Laboratories International Inc
NYSE· Healthcare· Diagnostics & Research· CUSIP 159864107
$339.66-1.51%Price as of Oct 23, 00:43 UTC · updated once a day, after the close
At a glance
Charles River Laboratories International Inc (CRL) is listed on NYSE and classified in Diagnostics & Research, part of the Healthcare sector. It is headquartered in Wilmington, United States and has 18,300 employees. The company is worth $16.36B. Revenue was $4.02B in fiscal 2025, down 0.9% from the year before. It reported a net loss of $144.34M. The share price is 3.3% below its 52-week high of $351.21. 3 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Ken Griffin (Citadel Advisors), at $270.7M. In that quarter, 3 of them reduced the position. Over the last 30 days, company insiders bought $2.97K and sold $302.58K of its stock on the open market. All of those sales were scheduled in advance under 10b5-1 plans.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $16.36B
- P/E
- —
- Forward P/E
- 26.6x
- P/B
- 5.7x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- -$4.73
- ROE
- -7.52%
- Profit margin
- -5.96%
- Revenue growth
- -2.70%
- Beta
- 1.40
- 52-week high
- $351.21
- 52-week low
- $146.20
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -18.0% over 5Y.
today you would have $668.96▼ -33.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 18 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $199.48 | $184.60 | $236.40 | $217.90 | $376.78 | $249.86 | $152.76 | $113.18 | $109.45 | $76.19 | $80.39 | $63.64 | $53.04 | $37.47 | $27.33 | $35.54 | $33.69 | $26.20 |
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
$133.62
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Operating
$83.36
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
Dividends
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| EXELExelixis Inc | $65.31 | 20.4x | 8.8x | 0.00% | 44.39% | $16.18B |
| ASNDAscendis Pharma A/S | $242.99 | 18.6x | 9.9x | 0.00% | 118.78% | $15.99B |
| RVTYRevvity Inc | $157.36 | 74.9x | 2.4x | 0.18% | 3.21% | $17.56B |
| SOLVSolventum Corp | $87.45 |
About the company
- 18,300
- Wilmington, United States